Bristol Myers Squibb (CELG-RI) Exchange Rate Effect (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Exchange Rate Effect of -$10.0 million for Q2 2026, down 107.81% year-over-year from $128.0 million in Q2 2025, and up 79.17% quarter-over-quarter from -$48.0 million in Q1 2026.
Bristol Myers Squibb (CELG-RI) Exchange Rate Effect (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Exchange Rate Effect for 18 consecutive years, with -$10.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Exchange Rate Effect fell 107.81% year-over-year to -$10.0 million; the TTM figure through Jun 2026 stood at -$57.0 million (down 145.97% YoY), while the FY2025 annual figure was $195.0 million, up 242.34% from the prior year.
- Exchange Rate Effect climbed to -$10.0 million in Q2 2026 per CELG-RI's latest filing, from -$48.0 million in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $128.0 million in Q2 2025 and bottomed at -$147.0 million in Q4 2024.
- Historically, Exchange Rate Effect has averaged $666666.7 across 5 years, with a median of -$6.0 million in 2023.
- Annual changes were most pronounced in 2022 — Exchange Rate Effect slumped 494.44% — and 2025, when it jumped 681.82%.
- Bristol Myers Squibb's Exchange Rate Effect stood at $95.0 million in 2022, then declined by 17.89% to $78.0 million in 2023, then slumped by 288.46% to -$147.0 million in 2024, then jumped by 103.4% to $5.0 million in 2025, then slumped by 300.0% to -$10.0 million in 2026.
- Business Quant data shows CELG-RI's Exchange Rate Effect at -$10.0 million in Q2 2026, -$48.0 million in Q1 2026, and $5.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.44 Bn | 632.68 Bn | 17.26 Bn | 5.00 Mn |
| 2 | AbbVie | 470.20 Bn | 463.63 Bn | 12.70 Bn | -7.00 Mn |
| 3 | Merck | 378.55 Bn | 371.41 Bn | 12.21 Bn | -37.00 Mn |
| 4 | Novartis Ag | 302.90 Bn | 295.21 Bn | 11.24 Bn | -18.00 Mn |
| 5 | Astrazeneca | 258.41 Bn | 253.51 Bn | 12.86 Bn | 9.00 Mn |
| 6 | Amgen | 237.59 Bn | 223.61 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 183.64 Bn | 180.46 Bn | 6.22 Bn | -19.00 Mn |
| 8 | Pfizer | 160.71 Bn | 149.01 Bn | 10.94 Bn | -4.00 Mn |
| 9 | Gsk | 106.18 Bn | 102.01 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | -10.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.00 Mn |
| Jun 30, 2026 | -10.00 Mn |
| Mar 31, 2026 | -48.00 Mn |
| Mar 31, 2026 | -48.00 Mn |
| Dec 31, 2025 | 5.00 Mn |
| Dec 31, 2025 | 5.00 Mn |
| Sep 30, 2025 | -4.00 Mn |
| Sep 30, 2025 | -4.00 Mn |
| Jun 30, 2025 | 128.00 Mn |
| Jun 30, 2025 | 128.00 Mn |
| Mar 31, 2025 | 66.00 Mn |
| Mar 31, 2025 | 66.00 Mn |
| Dec 31, 2024 | -147.00 Mn |
| Dec 31, 2024 | -147.00 Mn |
| Sep 30, 2024 | 77.00 Mn |
| Sep 30, 2024 | 77.00 Mn |
| Jun 30, 2024 | -22.00 Mn |
| Jun 30, 2024 | -22.00 Mn |
| Mar 31, 2024 | -45.00 Mn |
| Mar 31, 2024 | -45.00 Mn |